By Fineline Cube 
Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering partnership designed to expand China’s digestive-health market. The collaboration leverages JD’s consumer analytics to introduce a cylindrical package tailored for e-commerce shipping and social-media appeal among younger users. Positioned as a discreet alternative to traditional laxatives, the ready-to-drink oral solution aims to enhance user convenience and experience.
JD Health’s Data-Driven Strategy
JD Health will utilize its nationwide data engine and omnichannel network—including B2C, O2O, and brick-and-mortar pharmacies—to boost product awareness and establish an integrated constipation-care ecosystem. This approach underscores JD’s commitment to enhancing consumer health experiences through innovative distribution and engagement channels.
Future Collaborations
The companies have pledged to jointly launch additional products and expand health-education campaigns. This collaboration represents a significant step in addressing digestive health needs in China, combining Bayer’s pharmaceutical expertise with JD Health’s digital and logistical capabilities.-Fineline Info & Tech